<DOC>
	<DOCNO>NCT01034839</DOCNO>
	<brief_summary>In adult acute myeloid leukemia , especially &lt; 60 year age , high-dose cytarabine consolidation therapy show influence survival , appropriate dose define .</brief_summary>
	<brief_title>High-dose Cytarabine Survival AML</brief_title>
	<detailed_description>Background In adult acute myeloid leukemia , especially &lt; 60 year age , high-dose cytarabine consolidation therapy show influence survival . However , appropriate dose define . We evaluate survival cytarabine consolidation therapy three different dos . Design Methods We conduct single-center , retrospective study involve 499 acute myeloid leukemia patient , age 18-92 year , evaluate 1978 2007 . Of 499 patient , 400 receive curative treatment 203 receive cytarabine consolidation . The latter divide three group : low-dose ( receive &lt; 1.5 g/m2 i.v . cytarabine , every 12 h , 3 alternate day , 4 cycle ) ; medium-high-dose ( &lt; 45.45 g—the median dose—by end cycle ) ; very-high-dose ( ≥ 45.45 g end cycle ) . Results Among 400 patient receive curative treatment , five-year survival 22.8 % ( 91 patient ) . Cytarabine consolidation dose independent determinant survival ( significant difference find among group ) , whereas age , karyotype , induction protocol , French-American-British classification etiology . In comparison very-high-dose group , risk death 3.871 time ( 95 % CI , 1.043 14.370 time ) high high-dose group ( p=0.043 ) 9.775 time ( 95 % CI , 2.493 38.320 time ) high low-dose group ( p=0.001 ) , assume , case , age , karyotype , French-American-British classification etiology acute myeloid leukemia constant . Conclusions Consolidation therapy high-dose cytarabine appear improve survival patient acute myeloid leukemia .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>clinical diagnosis acute myeloid leukemia age 18 year must treat potentially curative therapy child age less 18 year palliative therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>92 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>acute myeloid leukemia</keyword>
	<keyword>prognosis</keyword>
	<keyword>cytarabine</keyword>
</DOC>